Tag: Africa

Quantexa Reaches Centaur Status, Surpassing $100 Million ARR

Quantexa’s strong innovation pipeline, global presence and go-to-market strategy set the stage for continued growth, supporting its expanding customer base in building trusted data foundations for AI LONDON, Oct. 29, 2024 (GLOBE NEWSWIRE) — Quantexa, a global leader in Decision Intelligence (DI) solutions for the public and private sectors, announced

2ONE® Nicotine Pouches Joins MBM Motorsports in Multi-Race Sponsorship

Josh Bilicki and Chad Finchum will each get a start in the 2ONE Pouches No. 66 NASCAR Cup Series entry STATESVILLE, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) — Motorsports Business Management (MBM Motorsports) has signed 2ONE® Nicotine Pouches (“Twenty-One”) to a multi-race sponsorship deal to conclude the 2024 NASCAR Cup

2ONE® Nicotine Pouches Joins MBM Motorsports in Multi-Race Sponsorship

Josh Bilicki and Chad Finchum will each get a start in the 2ONE Pouches No. 66 NASCAR Cup Series entry STATESVILLE, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) — Motorsports Business Management (MBM Motorsports) has signed 2ONE® Nicotine Pouches (“Twenty-One”) to a multi-race sponsorship deal to conclude the 2024 NASCAR Cup

2024 Business School Applications Skyrocket amidst Economic Uncertainty

GMAC’s annual survey shows demand growth is five times greater than the pandemic boom RESTON, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) — Across the globe, total applications to graduate business school programs in 2024 increased an impressive 12 percent from 2023 to 2024. This is a sharp reversal from the

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are